Consumer Medicine Information (CMI) about Sacubitril/Valsartan Alphapharm intended for persons living in Australia.

KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema ...

Pharvaris announced abstract acceptances for the 2025 National Summit on hereditary angioedema, featuring multiple poster presentations on deucrictibant.

Sebetralstat is poised to become the first oral on-demand treatment for hereditary angioedema in Canada. This treatment addresses a critical need for patients living with HAE - a rare and potentially ...

Hereditary angioedema (HAE) is a rare genetic disease resulting in deficiency or dysfunction in the C1 esterase inhibitor (C1INH) protein and subsequent uncontrolled activation of the kallikrein ...

BOGOTA, Colombia-- (BUSINESS WIRE)--Pint Pharma is pleased to announce that the Colombian National Food and Drug Surveillance Institute (INVIMA) has approved ORLADEYO®, indicated for the prophylaxis ...

Valsartan Valsartan (Diovan, Novartis) was the second nonpeptide AT-II type 1- receptor antagonist available for the treatment of hypertension. Valsartan is rapidly absorbed from the ...